CN110699325A - 基于CRISPR/Cas9技术的血浆肿瘤突变负荷检测质控品的制备方法 - Google Patents
基于CRISPR/Cas9技术的血浆肿瘤突变负荷检测质控品的制备方法 Download PDFInfo
- Publication number
- CN110699325A CN110699325A CN201910975591.7A CN201910975591A CN110699325A CN 110699325 A CN110699325 A CN 110699325A CN 201910975591 A CN201910975591 A CN 201910975591A CN 110699325 A CN110699325 A CN 110699325A
- Authority
- CN
- China
- Prior art keywords
- tmb
- quality control
- crispr
- control product
- plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明提供一种基于CRISPR/Cas9技术的血浆肿瘤突变负荷检测质控品的制备方法,包括如下步骤:(1)突变细胞株的制备,以CRISPR/Cas9技术作为基础,通过体外转染技术构建带有TP53基因突变的细胞株;(2)不同TMB频率阳性混合克隆的制备与验证;(3)人工模拟血浆游离DNA TMB检测质控品的制备与验证。本发明中,TMB频率精准可控,确保质控品的质量;提供了三个水平的TMB质控物质,有助于构建完整、严密、可靠的二代测序质量控制体系。
Description
技术领域
本发明属于生物技术领域,具体涉及一种基于CRISPR/Cas9技术的血浆肿瘤突变负荷检测质控品的制备方法。
背景技术
CRISPR/Cas9通过对预设的DNA位点进行切割,造成DNA双链断裂(DSB,doublestrandbreak)。这种DNA的损伤可以启动细胞内的修复机制,通过同源介导的修复(HR,homology-directedrepair),高保真地实现基因的精确编辑。CRISPR/Cas9技术以自己操作的便捷性,高效的基因编辑能力获得青睐,成为当下科研工作者的新宠儿。各大实验室纷纷加入开发CARISPR/Cas9技术的行列中,媒体也将之评为21世纪最有影响的十大技术之一。
发明内容
本发明要解决的技术问题是提供一种基于CRISPR/Cas9技术的血浆肿瘤突变负荷检测质控品的制备方法,TMB频率精准可控,确保质控品的质量;提供了三个水平的TMB质控物质,有助于构建完整、严密、可靠的二代测序质量控制体系。
为解决上述技术问题,本发明的实施例提供一种基于CRISPR/Cas9技术的血浆肿瘤突变负荷检测质控品的制备方法,其特征在于,包括如下步骤:
(1)突变细胞株的制备
以CRISPR/Cas9技术作为基础,通过体外转染技术构建带有TP53基因突变的细胞株;
(2)不同TMB频率阳性混合克隆的制备与验证;
(3)人工模拟血浆游离DNA TMB检测质控品的制备与验证。
其中,步骤(1)包括如下具体步骤:
(1-1)靶细胞:选择HEK293T细胞株;
(1-2)靶细胞基础TMB水平验证:采用Illmina Miseq测序平台对HEK293T细胞基因组DNA行全外显子测序,分析其基础TMB水平,从而验证其天然低TMB水平;
(1-3)靶基因选择:选择肿瘤基因组TMB作为候选编辑基因;
(1-4)sgRNA设计:利用CHOPCHOP在线工具进行sgRNA的设计,依据靶向性差与切割活性高两项原则构建sgRNA如下:
CACCATTGGCAATGAGCGGTTC,
AGGTCTTGCGGATGTCCACGT,
GCCGACGACAGCCTGAGCAA,
CGCCACAGCCCGCAGACTTC;
(1-5)带有不同sgRNA的CRISPR/Cas9表达载体筛选:构建质粒转染HEK293T细胞,采用T7EI错配酶切方法对sgRNA的切割效率进行鉴定,选取切割效率最高的5~10种sgRNA/Cas9共表达质粒,并进行二代测序验证突变存在,最终完成突变细胞株的构建。
其中,步骤(2)的具体步骤为:
(2-1)将TMB水平定义如下:
(2-2)阳性混合克隆验证:采用Illumina Miseq平台对上述细胞提取DNA进行WES测序检测,从而对CRISPR/Cas9的多位点编辑技术进行确认,结果如下:
高TMB水平:29.78±3.65mutations/Mb;
中TMB水平:13.67±2.17mutations/Mb;
低TMB水平:6.54±1.18mutations/Mb;
阴性对照:未检出P53突变。
其中,步骤(3)的具体步骤为:
(3-1)人工模拟血浆游离DNATMB检测质控品的制备:按照比例将含有不同TMB水平的阳性单克隆HEK293细胞及阴性对照HEK293细胞进行混合,获取MAF为1%-5%的细胞混合物;提取前述混合细胞DNA,采用MNase进行消化,并与模拟血浆混合,最终制备获得不同TMB水平的人工模拟血浆游离DNATMB检测质控品;
(3-2)人工模拟血浆游离DNA TMB检测质控品的验证:
(3-2-1)毛细管电泳验证,采用Agilent 2100毛细电泳仪验证质控品DNA片段分布在147~166bp;
(3-2-2)WES验证,采用多平台对质控品进行WES检测,分析并验证各组TMB值,结果如下:
高TMB水平:25.78±4.05mutations/Mb;
中TMB水平:11.45±1.75mutations/Mb;
低TMB水平:5.86±1.03mutations/Mb;
阴性对照:未检出P53突变。
本发明的上述技术方案的有益效果如下:本发明中,TMB频率精准可控,确保质控品的质量;提供了三个水平的TMB质控物质,有助于构建完整、严密、可靠的二代测序质量控制体系。
附图说明
图1为本发明中HEK293T不包含P53突变、呈野生型的示意图;
图2为本发明中二代测序显示细胞P53存在大量突变的示意图;
图3为本发明中质控品TMB评率验证结果的示意图;
图4为本发明中安捷伦2100质检结果的示意图;
图5为本发明中血浆TMB质控品验证结果的示意图。
具体实施方式
为使本发明要解决的技术问题、技术方案和优点更加清楚,下面将结合附图及具体实施例进行详细描述。
本发明提供一种基于CRISPR/Cas9技术的血浆肿瘤突变负荷检测质控品的制备方法,包括如下步骤:
(1)突变细胞株的制备
以CRISPR/Cas9技术作为基础,通过体外转染技术构建带有TP53基因突变的细胞株
(1-1)靶细胞:选择HEK293T细胞株,原因为转染效率高,可单细胞生长,更为重要的是不带有前述肿瘤驱动基因且基础TMB率极低;
(1-2)靶细胞基础TMB水平验证:采用Illmina Miseq测序平台对HEK293T细胞基因组DNA行全外显子测序,分析其基础TMB水平,从而验证其天然低TMB水平,如图1所示;
(1-3)靶基因选择:选择肿瘤基因组TMB作为候选编辑基因;
国内外最新研究显示肿瘤基因组TMB频率与TP53突变具有显著相关性,同时此基因在多种实体瘤中均可发生高频突变,且与肿瘤进展密切相关;故选取此基因作为候选编辑基因;
(1-4)sgRNA设计:参考NCBI网站中“Nucleotide”所获TP53基因的CDS序列,利用CHOPCHOP在线工具进行sgRNA的设计,依据靶向性差与切割活性高两项原则构建sgRNA如下:
CACCATTGGCAATGAGCGGTTC,
AGGTCTTGCGGATGTCCACGT,
GCCGACGACAGCCTGAGCAA,
CGCCACAGCCCGCAGACTTC;
(1-5)带有不同sgRNA的CRISPR/Cas9表达载体筛选:构建质粒转染HEK293T细胞,采用T7EI错配酶切方法对sgRNA的切割效率进行鉴定,选取切割效率最高的5~10种sgRNA/Cas9共表达质粒(针对每一种基因),并进行二代测序验证突变存在(如图2所示),最终完成突变细胞株的构建。
(2)不同TMB频率阳性混合克隆的制备与验证
(2-1)将TMB水平定义如下:
(2-2)阳性混合克隆验证:采用Illumina Miseq平台对上述细胞提取DNA进行WES测序检测,从而对CRISPR/Cas9的多位点编辑技术进行确认,结果如下:
高TMB水平:29.78±3.65mutations/Mb;
中TMB水平:13.67±2.17mutations/Mb;
低TMB水平:6.54±1.18mutations/Mb;
阴性对照:未检出P53突变。
质控品TMB评率验证结果如图3所示。
(3)人工模拟血浆游离DNA TMB检测质控品的制备与验证
(3-1)人工模拟血浆游离DNATMB检测质控品的制备:按照比例将含有不同TMB水平的阳性单克隆HEK293细胞及阴性对照HEK293细胞进行混合,获取MAF为1%-5%的细胞混合物;提取前述混合细胞DNA,采用MNase进行消化,并与模拟血浆混合,最终制备获得不同TMB水平的人工模拟血浆游离DNATMB检测质控品;
(3-2)人工模拟血浆游离DNA TMB检测质控品的验证:
(3-2-1)毛细管电泳验证,采用Agilent 2100毛细电泳仪验证质控品DNA片段分布在100~140bp,如图4所示。
(3-2-2)WES验证,采用多平台(Illumina、Ion Proton)对质控品进行WES检测,分析并验证各组TMB值,结果如下:
高TMB水平:25.78±4.05mutations/Mb;
中TMB水平:11.45±1.75mutations/Mb;
低TMB水平:5.86±1.03mutations/Mb;
阴性对照:未检出P53突变。
血浆TMB质控品验证结果如图5所示。
本发明中,基于CRISPR-Cas9的基因编辑系统可简便、有效地制备出TMB频率精准可控,确保质控品的质量;此外,提供了三个水平的TMB质控物质,有助于构建完整、严密、可靠的二代测序质量控制体系。
以上所述是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明所述原理的前提下,还可以作出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (4)
1.一种基于CRISPR/Cas9技术的血浆肿瘤突变负荷检测质控品的制备方法,其特征在于,包括如下步骤:
(1)突变细胞株的制备
以CRISPR/Cas9技术作为基础,通过体外转染技术构建带有TP53基因突变的细胞株;
(2)不同TMB频率阳性混合克隆的制备与验证;
(3)人工模拟血浆游离DNA TMB检测质控品的制备与验证。
2.根据权利要求1所述的基于CRISPR/Cas9技术的血浆肿瘤突变负荷检测质控品的制备方法,其特征在于,步骤(1)包括如下具体步骤:
(1-1)靶细胞:选择HEK293T细胞株;
(1-2)靶细胞基础TMB水平验证:采用Illmina Miseq测序平台对HEK293T细胞基因组DNA行全外显子测序,分析其基础TMB水平,从而验证其天然低TMB水平;
(1-3)靶基因选择:选择肿瘤基因组TMB作为候选编辑基因;
(1-4)sgRNA设计:利用CHOPCHOP在线工具进行sgRNA的设计,依据靶向性差与切割活性高两项原则构建sgRNA如下:
CACCATTGGCAATGAGCGGTTC,
AGGTCTTGCGGATGTCCACGT,
GCCGACGACAGCCTGAGCAA,
CGCCACAGCCCGCAGACTTC;
(1-5)带有不同sgRNA的CRISPR/Cas9表达载体筛选:构建质粒转染HEK293T细胞,采用T7EI错配酶切方法对sgRNA的切割效率进行鉴定,选取切割效率最高的5~10种sgRNA/Cas9共表达质粒,并进行二代测序验证突变存在,最终完成突变细胞株的构建。
4.根据权利要求1所述的基于CRISPR/Cas9技术的血浆肿瘤突变负荷检测质控品的制备方法,其特征在于,步骤(3)的具体步骤为:
(3-1)人工模拟血浆游离DNATMB检测质控品的制备:按照比例将含有不同TMB水平的阳性单克隆HEK293细胞及阴性对照HEK293细胞进行混合,获取MAF为1%-5%的细胞混合物;提取前述混合细胞DNA,采用MNase进行消化,并与模拟血浆混合,最终制备获得不同TMB水平的人工模拟血浆游离DNATMB检测质控品;
(3-2)人工模拟血浆游离DNA TMB检测质控品的验证:
(3-2-1)毛细管电泳验证,采用Agilent 2100毛细电泳仪验证质控品DNA片段分布在147~166bp;
(3-2-2)WES验证,采用多平台对质控品进行WES检测,分析并验证各组TMB值,结果如下:
高TMB水平:25.78±4.05mutations/Mb;
中TMB水平:11.45±1.75mutations/Mb;
低TMB水平:5.86±1.03mutations/Mb;
阴性对照:未检出P53突变。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910975591.7A CN110699325A (zh) | 2019-10-14 | 2019-10-14 | 基于CRISPR/Cas9技术的血浆肿瘤突变负荷检测质控品的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910975591.7A CN110699325A (zh) | 2019-10-14 | 2019-10-14 | 基于CRISPR/Cas9技术的血浆肿瘤突变负荷检测质控品的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110699325A true CN110699325A (zh) | 2020-01-17 |
Family
ID=69199368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910975591.7A Pending CN110699325A (zh) | 2019-10-14 | 2019-10-14 | 基于CRISPR/Cas9技术的血浆肿瘤突变负荷检测质控品的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110699325A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111118167A (zh) * | 2020-03-31 | 2020-05-08 | 菁良基因科技(深圳)有限公司 | 一种肿瘤突变负荷标准品及其制备方法和试剂盒 |
CN111893178A (zh) * | 2020-08-24 | 2020-11-06 | 重庆市人口和计划生育科学技术研究院 | 一种α地中海贫血基因检测遗传参考物质及其制备方法 |
CN114182018A (zh) * | 2021-12-17 | 2022-03-15 | 北京医院 | 一种肿瘤突变负荷检测的质控品及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109880910A (zh) * | 2019-04-25 | 2019-06-14 | 南京世和基因生物技术有限公司 | 一种肿瘤突变负荷的检测位点组合、检测方法、检测试剂盒及系统 |
-
2019
- 2019-10-14 CN CN201910975591.7A patent/CN110699325A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109880910A (zh) * | 2019-04-25 | 2019-06-14 | 南京世和基因生物技术有限公司 | 一种肿瘤突变负荷的检测位点组合、检测方法、检测试剂盒及系统 |
Non-Patent Citations (2)
Title |
---|
JINGYU CAO ET AL.: "An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies", 《THE ONCOLOGIST》 * |
童琳等: "晚期非小细胞肺癌患者肿瘤突变负荷与靶向治疗疗效相关性", 《中国临床医学》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111118167A (zh) * | 2020-03-31 | 2020-05-08 | 菁良基因科技(深圳)有限公司 | 一种肿瘤突变负荷标准品及其制备方法和试剂盒 |
CN111893178A (zh) * | 2020-08-24 | 2020-11-06 | 重庆市人口和计划生育科学技术研究院 | 一种α地中海贫血基因检测遗传参考物质及其制备方法 |
CN114182018A (zh) * | 2021-12-17 | 2022-03-15 | 北京医院 | 一种肿瘤突变负荷检测的质控品及其制备方法 |
CN114182018B (zh) * | 2021-12-17 | 2023-10-03 | 北京医院 | 一种肿瘤突变负荷检测的质控品及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11306308B2 (en) | High-throughput CRISPR-based library screening | |
Brinkman et al. | Easy quantification of template-directed CRISPR/Cas9 editing | |
Bloh et al. | Deconvolution of complex DNA repair (DECODR): establishing a novel deconvolution algorithm for comprehensive analysis of CRISPR-edited sanger sequencing data | |
CN110699325A (zh) | 基于CRISPR/Cas9技术的血浆肿瘤突变负荷检测质控品的制备方法 | |
Inniss et al. | A novel Bxb1 integrase RMCE system for high fidelity site‐specific integration of mAb expression cassette in CHO cells | |
Xie et al. | An episomal vector-based CRISPR/Cas9 system for highly efficient gene knockout in human pluripotent stem cells | |
Li et al. | Metabolic engineering of Escherichia coli using CRISPR–Cas9 meditated genome editing | |
Vanegas et al. | Cpf1 enables fast and efficient genome editing in Aspergilli | |
CN108342480A (zh) | 一种基因变异检测质控物及其制备方法 | |
CN109880851B (zh) | 用于富集CRISPR/Cas9介导的同源重组修复细胞的筛选报告载体及筛选方法 | |
Vriend et al. | Assaying break and nick-induced homologous recombination in mammalian cells using the DR-GFP reporter and Cas9 nucleases | |
WO2023142594A1 (zh) | 一种精确无pam限制的腺嘌呤碱基编辑器及其应用 | |
Xu et al. | Optimized guide RNA structure for genome editing via Cas9 | |
Wyvekens et al. | Genome editing in human cells using CRISPR/Cas nucleases | |
WO2023093007A1 (zh) | 一种cho细胞基因nw_003614889.1内稳定表达蛋白质的位点及其应用 | |
Filippova et al. | Are small nucleolar RNAs “CRISPRable”? a report on box C/D small nucleolar RNA editing in human cells | |
Bodai et al. | Targeting double-strand break indel byproducts with secondary guide RNAs improves Cas9 HDR-mediated genome editing efficiencies | |
Schmieder et al. | A pooled CRISPR/AsCpf1 screen using paired gRNAs to induce genomic deletions in Chinese hamster ovary cells | |
van Schendel et al. | SIQ: easy quantitative measurement of mutation profiles in sequencing data | |
Yang et al. | Generation of isogenic single and multiplex gene knockout mice by base editing-induced STOP | |
CN112175984A (zh) | 基于合成基因和酿酒酵母同源重组机制的分子克隆方法 | |
Cui et al. | The TelN/tos-assisted precise targeting of chromosome segments (TAPE) | |
Rahman et al. | Correction of a CD55 mutation to quantify the efficiency of targeted knock-in via flow cytometry | |
CN114182018B (zh) | 一种肿瘤突变负荷检测的质控品及其制备方法 | |
Peng et al. | Development of a novel reference material for tumor mutational burden measurement based on CRISPR/Cas9 technology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200117 |
|
WD01 | Invention patent application deemed withdrawn after publication |